Related Experiment Video
Updated: May 9, 2026
11:02
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Pharmacometabonomics and personalized medicine
Jeremy R Everett1, Ruey Leng Loo, Francis S Pullen
1Medway Metabonomics Research Group, School of Science, University of Greenwich, Chatham Maritime, UK.
Annals of Clinical Biochemistry
|July 27, 2013
Summary
Pharmacometabonomics uses metabolite profiles to predict drug effects, improving personalized medicine. This approach considers genetics, environment, and the microbiome for enhanced drug efficacy and safety.
Area of Science:
- Pharmacometabonomics represents a novel scientific discipline focused on predicting drug responses.
- It integrates metabolomics with pharmacology to understand drug behavior in biological systems.
Background:
- Defined in 2006, pharmacometabonomics utilizes pre-dose metabolite profiles and mathematical modeling.
- It complements pharmacogenomics (PGx) and pharmacoproteomics in drug development and clinical application.
Purpose of the Study:
- To review the emerging field of pharmacometabonomics and its applications.
- To assess its potential in personalized medicine for optimizing drug efficacy and safety.
Main Methods:
- A comprehensive literature review was conducted using major scientific databases (PubMed, Web of Science).
- Search terms included various forms of 'pharmacometabonomics' and 'pharmacometabolomics' from October 2012 to April 2013.
Main Results:
- The field has grown significantly since 2006, with 21 original publications and 8 reviews.
- Applications span prediction of pharmacokinetics (PK), drug metabolism, efficacy, and safety in humans and animals.
Conclusions:
- Pharmacometabonomics holds significant promise for advancing personalized medicine by enhancing drug efficacy and patient safety.
- Its sensitivity to genetic and environmental factors, including the microbiome, makes it a powerful tool.
- It is predicted to become as important as pharmacogenomics (PGx) in the coming decades, offering complementary insights.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...